^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Non Small Cell Lung Cancer
    Drug:carboplatin (Tubulin polymerization promoter) +
    AiRuiKa (camrelizumab) (PD1 inhibitor) +
    pemetrexed (Thymidylate synthase inhibitor, THF dehydrogenase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    IASLC-WCLC 2020
    Title:

    P79.02 - Updated OS and Time to Second Progression with First-Line Camrelizumab Plus Chemo vs Chemo for Advanced Non-Squamous NSCLC

    Published date:
    01/12/2021
    Excerpt:
    ...median follow-up duration was 19.3 months (IQR 9.8−23.7). 35 (17.1%) patients in the camrelizumab plus chemo group and 18 (8.7%) in the chemo alone group...Camrelizumab plus chemo prolonged median overall survival, as compared with chemo alone (27.9 months [95% CI 21.9−not reached] vs 20.5 months [95% CI 15.9−24.­­4]; HR 0.73 [95% CI 0.55−0.96]; P=0.0117)...Benefits in OS and PFS2 with camrelizumab plus chemo were also found in patients with PD-L1 TPS ≥1% (Table)...
    Trial ID:
    NCT03134872